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Abstract
Purpose To analyse the modifications induced by two
different platelet-rich plasma (PRP) preparations on osteo-
arthritis (OA) synoviocytes, by documenting changes in
gene expression of factors involved in joint physiopathology.
Methods OA synoviocytes were cultured for 7 days in
medium with different concentrations of either P-PRP (a
pure platelet concentrate without leucocytes but with a
limited number of platelets), L-PRP (a higher platelet
concentrate containing leucocytes) or platelet-poor plasma
(PPP). Gene expression of interleukin (IL)-1beta, IL-6, IL-
8/CXCL8, tumour necrosis factor alpha, IL-10, IL-4, IL-
13, metalloproteinase-13, tissue inhibitor of metallopro-
teinase (TIMP)-1, (TIMP)-3, (TIMP)-4, vascular endothe-
lial growth factor, transforming growth factor beta1,
fibroblast growth factor (FGF)-2, hepatocyte growth factor
(HGF), hyaluronic acid (HA) synthases (HAS)-1, (HAS)-2,
and (HAS)-3 was analysed by RT-PCR. HA production
was determined in culture supernatants by ELISA.
Results IL-1b, IL-8 and FGF-2 were significantly induced
by L-PRP compared to both P-PRP and PPP; HGF was
down-modulated by L-PRP versus both P-PRP and PPP, and
an inverse dose–response influence was shown for all prep-
arations. Expression level of TIMP-4 was lower in the pre-
sence of L-PRP compared with P-PRP. HA production and
HAS gene expression did not seem to be modulated by PRP.
Conclusions L-PRP is able to sustain the up-regulation of
proinflammatory factors, (IL-1beta, IL-8 and FGF-2), together
with a down-modulation of HGF and TIMP-4 expression, two
factors that have been recognized as anti-catabolic mediators
in cartilage, thus supporting the need to further optimize the
PRP preparations to be applied in clinical practice.
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Introduction
Osteoarthritis (OA) is a common disease that will affect
almost half the population at some point in their life
through pain and decreased functional capacity [44].
Numerous approaches have been proposed as non-invasive
treatments with variable success rates, but none has clearly
shown to modify the natural history of the disease and can
be considered an ideal procedure for the treatment of joint
degenerative processes [29, 33].
Among the new emerging treatment options, injective
approaches based on the use of autologous blood deriva-
tives have been introduced into clinical use. In particular,
despite the lack of robust literature, there is increasing
interest in the local administration of platelet-rich plasma
(PRP) to provide a biological stimulus to regeneration [20].
Evidence to support its use has been gathered from the role
played in tissue healing, cellular recruitment, growth,
maturation and in modulating inflammation by several of
the platelet-derived bioactive molecules [13, 46, 57, 58].
Based on this biological rationale, platelet concentrates
have been used as a minimally invasive injective treatment
for cartilage degeneration and OA for almost a decade [18,
25, 55, 60]. Recently some high-level trials showed overall
positive results, thus confirming the potential of this bio-
logical treatment approach for knee cartilage degeneration
and OA [19, 47, 51]. However, a deeper analysis showed
that the published findings were not consistent and some-
times contradictory.
Among the possible explanations for these contradictory
findings, we can hypothesize differences in patient selec-
tion, treatment application modality and methodological
mistakes. However, what surely emerges from the litera-
ture analysis is that the main limit is currently the hetero-
geneity of products used and the lack of knowledge about
their mechanism of action and therefore their appropriate
indications, and which patients or pathology phase might
benefit most from this biological approach. In particular,
PRP is defined as a blood derivative with a higher platelet
number compared with whole blood before centrifugation
and the numerous preparation methods differ not only in
platelet concentration, but also in the presence of others
cells, such as white blood cells, whose role in the PRP
mechanism of action is still controversial [1, 15, 17, 24]. In
fact, some authors attribute deleterious effects to the pre-
sence of leucocytes in PRP preparation, due to the release
of inflammatory mediators, proteases and reactive oxygen
by these cells [9, 27]. On the other hand, leucocytes might
be considered as a source of cytokines and enzymes that
appear to be involved in the infection prevention [43].
The majority of the studies concerning clinical response
and in vitro PRP effects on joint cells are concentrated on
cartilage tissues [34, 54], while there are currently few
studies concerning the effect on synovial tissue (Reviewed
in [22]). In the last few years, together with cartilage and
bone, a growing body of evidence has highlighted the
relevance of synovial tissue as an active player in inducing
the progressive OA joint damage, via the release of soluble
inflammatory factors that contribute to increasing and
perpetuating cartilage damage [26, 37, 52], Therefore,
considerable part of the symptomatic improvement
obtained with PRP injections might be due to an interaction
between the released molecules and the synovial tissue.
Furthermore, majority of the previously reported studies
have evaluated the biological effect of PRP up to a maxi-
mum of 96 h, and then, long-term investigation on bio-
logical effects induced by PRP is needed, in order to
address another debated clinical issue relating to the timing
of PRP administration.
Bearing in mind these issues, the aim of this study was
to analyse the modifications induced by PRP on OA
synoviocytes in vitro and document changes in gene
expression of an extended panel of molecules implicated in
the physiopathology of the joint environment, including
inflammatory and anti-inflammatory cytokines, growth
factors, extracellular matrix-degrading enzyme and their
inhibitors.
Moreover, since the abbreviation PRP includes several
heterogeneous products, a secondary aim was to compare
the effects of two of the main procedures on synoviocytes,
which are already used in clinical practice, based on two
PRP preparation approaches that differ both in amount and
type of concentrated cells.
Two experimental key points were considered: first, an
incubation time point of 7 days was chosen to reproduce
the scheduled timing of PRP administration in OA treat-
ment, usually performed according to a series of repeated
injections on a weekly basis [19]. Second, to mimic the
therapeutic condition in the joint environment, the dilutions
of the PRP entire preparations (not only the released
supernatant) were allowed to clot directly in the culture
plates, by taking advantage from the TranswellTM device to
avoid cell–cell contact.
The research hypothesis was that PRP biological effects
may be sustained up to 7 days and that the difference in
platelet and leucocytes concentration in PRP preparations
as well as the use of different PRP amount may lead to
different response.
Materials and methods
Seven healthy men (age range 27–38 years) were enrolled
on a voluntary basis to undergo a blood sample collection
(200 ml per subject). Exclusion criteria were systemic
disorders, infections, smoking, non-steroidal anti-
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inflammatory drug use 5 days before blood donation,
haemoglobin values lower than 11 g/dl and platelet values
lower than 150 9 103/ll. Subject anonymity was assured
by assigning a code to each sample.
Preparation of platelet concentrates
PRPwas prepared according to two different strategies: a one-
spinning procedure, aimed at obtaining a pure platelet con-
centrate without leucocytes but with a limited number of
platelets through one centrifugation, and a two-spinning pro-
cedure, aimed at obtaining a higher platelet concentration but
with the presence of leucocytes through two centrifugations.
In more detail, for the one-spinning pure PRP (P-PRP)
procedure, a 45-ml venous blood sample was divided into
five tubes containing 1 ml of trisodium citrate solution
(3.8 %) and centrifuged (460g for 8 min). Then, 1 ml/tube of
the platelet-rich supernatant on the red blood cell pellet was
collected, while carefully avoiding leucocyte harvesting [3,
48]. For the two-spinning leucocyte PRP (L-PRP) procedure,
a 150-ml venous blood sample was collected in a bag con-
taining 21 ml of sodium citrate and centrifuged at 730g for
15 min. Most of the red blood cells were eliminated, and the
resulting plasma and buffy-coat were transferred to a sepa-
rate bag through a closed circuit. After a second centrifu-
gation at 3,800g for 10 min, the supernatant was collected to
produce PRP.During the second centrifugation platelet, poor
plasma (PPP) was also collected and used as the control [48].
The platelet and the white blood cell concentrations were
determined by a haematology analyser (COULTER LH
750): linearity was 5–1,000 9 103/ll for platelet count and
0.1–100 9 103/ll for white blood cell count.
Both PRP preparations and PPP were divided into two
aliquots, one used for cell culture supplementation and the
other one for released factor evaluations.
Evaluation of factors released from platelet gel
Each sample of PRP and PPP preparations was activated
with 10 % CaCl2 (22.8 mM final concentration) and
incubated for 7 days at 37 C in 5 % CO2, in agreement
with cell culture scheduled time point and PRP therapeutic
administration in OA [19].
After centrifugation (for 15 min at 2,800g at 20 C), the
released supernatant was collected and frozen at -30 C
until used for evaluating interleukin (IL)-1b, fibroblasts
growth factor (GF) 2 (FGF-2), hepatocyte GF (HGF),
platelet-derived GF AB/BB (PDGF AB/BB), transforming
GF (TGF-b1), and vascular endothelial GF (VEGF) con-
centrations (Standard range IL-1b 28,830.00–1.76 pg/ml;
FGF-2 18,336.00–1.12 pg/ml; HGF 37,910.00–2.31 pg/ml;
PDGF AB/BB 10,000.00–0.64 pg/ml; TGF-b1 30,019.
00–1.83 pg/ml; VEGF 28,440.00–1.79 pg/ml). Samples
were assayed in duplicate and factors simultaneously eval-
uated using commercially available bead-based sandwich
immunoassay kits (Bio-Rad Laboratories, Hercules, CA,
USA and Millipore Corporation, Billerica, MA, USA) [39].
Intra-assay and inter-assay coefficients of variation were,
respectively, estimated between 2–9 % and 5–12 %.
The immunocomplexes formed on distinct beads were
quantified by using the Bio-Plex Protein Array System (Bio-
RadLaboratories). Datawere analysed by using the Bio-Plex
Manager software version 6.0 (Bio-Rad Laboratories).
Standard levels between 70 and 130 % of the expected val-
ues were considered accurate and were used.
Cell isolation and culture
Synovial fibroblasts were isolated from patients with OA
(n = 3 Kellgren–Lawrence grade II–III [32]) undergoing
joint surgery. The cells were isolated by enzymatic
digestion. Briefly, the synovial tissue was washed twice in
phosphate-buffered saline (PBS) and minced into small
pieces. Subsequently, two digestions were performed on
synovial tissue: the first one with 0.1 % trypsin (Sigma-
Aldrich) in PBS at 37 C, 5 % CO2 for 30 min, the
second one with 0.1 % collagenase P (Roche) at 37 C
for 1 h under constant rotation. The resulting cell sus-
pension was filtered and centrifuged at 500g for 10 min.
The cells were seeded into culture flasks and maintained
with OPTIMEM (Gibco-BRL, Life Technologies Grand
Island, NY, USA) culture medium supplemented with
100 U/ml penicillin, 100 lg/ml streptomycin (Invitrogen,
Carlsbad, CA, USA) in a humidified atmosphere at 37 C
with 5 % CO2. All experiments were performed on cells
obtained between the third and fifth passage.
Subconfluent cultures of synoviocytes were trypsinized,
and cell viability was assessed by eosin dye exclusion; the
cells were plated at a density of 20,000–25,000 cells/cm2 in
12-well tissue-culture plates andmaintainedwith serum-free
culture medium (prepared as previously described) for 24 h.
Then, culture mediumwas supplemented with either P-PRP,
L-PRP or PPP obtained from each subject (n = 7) at 5, 10 or
20 % (vol/vol) previously activated with 10 % calcium
chloride (CaCl2 22.8 mM final concentration) to produce a
platelet gel and release the granule content. The incubation
period was 7 days, during which time the culture medium
was not changed. To maintain PRP-activated platelets in
contact with synoviocyte monolayers avoiding direct mix-
ing, a Transwell device was used (pore 0.4 lm; Corning,
Costar). All experiments were run in parallel. Cell viability
was evaluated using the Alamar blue colorimetric assay
(AbD Serotec, UK) on day 0, 1, 3 and 7. Briefly, cells were
incubated with 10 % Alamar Blue, and after 3 h, the fluo-
rescence was read at 540-nm excitation–590-nm emission
wavelength, using a microplate-reader (CytoFluorTM 2350,
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Millipore, Bedford, MA, USA). Absorbance was directly
proportional to the number of living cells in the culture, as
indicated by the manufacturer’s data sheet. All cultures uti-
lized for the subsequent experiments showed a number of
living cells C90 %.
At the end of the incubation time (7 days) culture,
supernatants were collected and maintained at -80 C
until their use in ELISA test and synovial fibroblasts were
lysed for RNA extraction.
Synovial fibroblasts gene expression analysis
Samples were assayed with real-time quantitative reverse
transcriptase polymerase chain reaction (RT-PCR) for IL-
1b, IL-4, IL-6, IL-8/CXCL8, IL-10, IL-13, tumour necrosis
factor (TNF)a, VEGF, TGF-b, FGF-2, HGF, metallopro-
teinase (MMP)-13, tissue inhibitor of metalloproteinase
(TIMP)-1, TIMP-3, TIMP-4, hyaluronic acid synthases
(HAS)-1, HAS-2, and HAS-3 gene expression.
Total RNA was isolated using TRIZOL reagent (Invit-
rogen) following the manufacturer’s recommended proto-
col. RNA was reverse-transcribed using superscript first-
strand kit (Invitrogen).
RNA-specific primers for PCR amplification (Table 1)
were generated from GeneBank sequences using Primer 3
Software. Real-time PCR was run on the LightCycler
Instrument (Roche) using the SYBR Premix Ex Taq (Ta-
KaRa biotechnology), and the increase in PCR product was
monitored for each amplification cycle by measuring the
increase in florescence due to the binding of SYBR Green I
Dye to dsDNA. Technical specifications of light cycler
instrument used to perform PCR allow to have a uniform
temperature for all samples during each run of PCR,
increasing the reproducibility of the data. The crossing point
values were determined for each sample, and specificity of
the amplicons was confirmed by melting curve analysis.
Amplification efficiency of each amplicon was evaluated
using tenfold serial dilutions of positive control cDNAs and
calculated from the slopes of log input amounts plotted
versus crossing point values. They all were confirmed to be
high ([92 %) and comparable; mRNA levels for each target
gene were calculated normalized to glyceraldehyde-3
phosphate dehydrogenase (GAPDH, reference gene), and
according to the DDCt method, the data were calculated as
the ratio of each gene to GAPDH and expressed as ‘‘Number
of molecules per 100,000 GAPDH’’.
Measurement of HA levels
HA in cell culture supernatants was evaluated using com-
mercial DuoSet ELISA kit (R&D Systems) following the
manufacturer’s instructions. A six-point standard curve
using threefold serial dilutions and a high standard of
90,000 ng/mL was performed and run in replicate (coeffi-
cient of variation average 18 %). The accuracy of the
methods was assessed by evaluating the agreement between
the expected andmeasured values by Bland–Altman plot (all
difference between repeated measures and expected values
did not exceed 95 % confidence interval). Reliability of the
test was estimated by Cronbach’s alpha coefficient ([0.99).
A four-parameter logistic (4-PL) curve-fit based on standard
optic density values was used to calculate hyaluronan con-
centrations considering three decimals. The low molecular
weight (15–40 kDa),mediummolecularweight (75–350 kDa)
and high molecular weight ([950 kDa) forms of Hyaluronan
are all detected in this assay. These results were normalized for
cell number and expressed as ng/106 synoviocytes.
Ethics committee approval
The study was approved by the Institutional Review Board
and by Ethics Committee of Rizzoli Orthopedic Institute
(ID no. 8342 of 2/04/2010). Written informed consent was
signed by each subject.
Statistical analysis
Data concerning the characterization of the different PRP
preparations were analysed by Friedman’s test for multiple
comparison of pared data and, when significant, followed
by Bonferroni’s post hoc correction for multiple compari-
sons (value of p\ 0.017 was considered significant after
Bonferroni’s correction).
Results obtained by gene expression analysis and
assessment of hyaluronic acid production were analysed by
the general linear model (GLM).
Since data presented a skewed distribution, not fulfilling
the hypothesis of normality, appropriate transformations
were applied according to the following formula: y
0
= -
log 10(y ? 1). All the resulting data fulfilled the normality
assumption as verified by the Kolmogorov–Smirnov test.
The GLM was used according to treatment condition (L-
PRP, P-PRP, PPP), dose (5, 10, 20 %) and their combi-
nations as fixed effects and the patient as a random effect.
Partial Eta squared (g p
2) was considered as evidence of the
strength of the combination (effect size) between the fixed
effects and gene expression levels of target molecules. The
Sidak correction was applied for multiple comparisons.
Value of p\ 0.05 was considered significant.
Spearman’s correlation analysis was used to assess
relationships between gene expression levels and platelet/
leucocyte concentrations.
When GLM analysis was significant according to dose
or treatment*dose association, the Kendall Tau correlation
analysis was used to assess relationships between gene
expression levels and doses of each preparation.
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A value of p\ 0.05 was considered significant.
Statistical analysis was carried out using SPSS v.19.0
(IBM Corp., Armonk, NY, USA) and GraphPad Prism for
Windows (CA, USA).
Results
Characterization of the different PRP preparations
Platelet concentrations were significantly different among
the three L-PRP, P-PRP and PPP preparations (Friedman’s
Anova p\ 0.001), and were also significantly different
from one another (Bonferroni’s post hoc test, p\ 0.017).
White blood cells were present in L-PRP preparation,
whereas they were almost undetectable in PPP and P-PRP
(Table 2).
In the different PRP and PPP preparations, excluding
FGF-2 that showed similar releases among the prepara-
tions, IL-1b, HGF, PDGF AB/BB, TGF-b1, and VEGF
concentrations were different (Friedman’s Anova p\ 0.01,
at least) (Table 3). In particular, IL-1b and VEGF con-
centrations were similar in PPP and P-PRP and both lower
than those in the L-PRP preparation. HGF and TGF-b1
Table 1 List of primers used in
Real-Time PCR
TIMP-4 was purchased from
Qiagen (Hilden, Germany) (Cat
no. PPH00889E)
RNA template Primer sequences (50–30) Annealing temperature (C) References
GAPDH 50-CCTGGCCAAGGTCATCCATG 60 Primer 3
30-CGGCCATCACGCCACAGTT
IL-1b 50-GTGGCAATGAGGATGACTTGTT 60 Primer 3
30-TGGTGGTCGGAGATTCGTAG
IL-6 50-TAGTGAGGAACAAGCCAGAG 60 Primer 3
30-GCGCAGAATGAGATGAGTTG
IL-8 50-CCAAACCTTTCCACCC 60 Primer 3
30-ACTTCTCCACAACCCT
TNF-a 50-AGCCCATGTTGTAGCAAACC 60 Primer 3
30-ACCTGGGAGTAGATGAGGTA
VEGF 50-TGATGATTCTGCCCTCCTC 60 Primer 3
30-GCCTTGCCTTGCTGCTC
FGF-2 50-CGGCTGTACTGCAAAAACGG 60 Primer 3
30-TTGTAGCTTGATGTGAGGGTCG
HGF 50-ATACTCTTGACCCTCACACC 60 Primer 3
30-TGTAGCCTTCTCCTTGACCT
TGF-b 50-CAACAATTCCTGGCGATACCT 60 Primer 3
30-TAGTGAACCCGTTGATGTCC
HAS-1 50-TGGTGCTTCTCTCGCTCTACG 60 [14]
30-GAACTTGGCAGGCAGGAGG
HAS-2 50-AAATGGGATGAATTCTTTGTTTATG 60 [14]
30-GGCGGATGCACAGTAAGGAA
HAS-3 50-CAGCTGATCCAGGCAATCGT 60 [14]
30-TGGCTGACCGGATTTCCTC
TIMP-1 50-CCGACCTCGTCATCAG 60 Primer 3
30-GTTGTGGGACCTGTGGAA
TIMP-3 50-CCTTGGCTCGGGCTCATC 60 Primer 3
30-GGATCACGATGTCGGAGTTG
IL-4 50-CAGTTCCACAGGCACAAG 60 Primer 3
30-CTGGTTGGCTTCCTTCACA
IL-13 50-GCACACTTCTTCTTGGTC 60 Primer 3
30-TGAGTCTCTGAACCCTTG
IL-10 50-CTTTAAGGGTTACCTGGGTTG 60 Primer 3
30-CTTGATGTCTGGGTCTTGG
MMP-13 50-TCACGATGGCATTGCT 60 Primer 3
30-GCCGGTGTAGGTGTAGA
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concentrations were lower in PPP than in P-PRP and
L-PRP, but not significantly different between the two PRP
preparations, whereas the PDGF AB/BB concentration
progressively and significantly increased from PPP, to
P-PRP, and then to L-PRP. All these factors showed
increased or stable (PDGF AB/BB) concentrations after
7 days of incubation compared with those observed after
1 h of activation (not shown).
Gene expression analysis of factors involved in joint
physiopathology
Pro-inflammatory factors, anti-inflammatory and/or anti-
catabolic factors
Gene expression analysis indicated that IL-1b and IL-8/
CXCL8 were significantly induced by L-PRP compared
with both P-PRP and PPP (IL-1 b: p\ 0.0005 L-PRP vs.
P-PRP, p = 0.008 L-PRP vs. PPP; IL-8: p = 0.002 L-PRP
vs. P-PRP, p = 0.008 L-PRP vs. PPP) (Fig. 1). Moreover,
L-PRP also had a dose–response effect (Kendall Tau, IL-
1b p = 0.013, IL-8 p = 0.011). Furthermore, if we con-
sider the combined dose treatment effect on IL-1b gene
expression, the dose–response curve showed a significantly
different incremental trend induced by L-PRP from those
of both P-PRP and PPP (p = 0.003) (Fig. 1). No signifi-
cance between preparations was found on IL-6, IL-10 and
TNF-a gene expression rate (Fig. 1), whereas IL-4 and IL-
13 gene expression levels were not detectable in cultured
synovial fibroblasts.
Growth factors, cartilage matrix-degrading enzymes
and their inhibitors
Among GFs genes, VEGF and TGF-b were not differently
modulated by the preparations (Fig. 2).
Interestingly, PRP preparations have an opposite effect
on HGF and FGF-2 expression, due to their composition.
Indeed, HGF expression is significantly down-modulated
by L-PRP compared to both PRP and PPP (p\ 0.0005
Table 2 Platelet and white blood cell concentrations in the different plasma preparations
PPP P-PRP L-PRP
Platelet number/mm3 9,000 (6,500–11,500) 158,000 (83,000–343,000) 963,000 (793,000–995,000)
WBC/mm3 0 \200 5,400 (4,300–6,000)
Results are expressed as medians and (interquartile ranges) of seven donors
PPP platelet-poor plasma, P-PRP pure platelet-rich plasma, L-PRP leucocyte platelet-rich plasma, WBC white blood cells
Table 3 Soluble factor concentrations in the different plasma preparations after 7 days of incubation
Soluble factors PPP P-PRP L-PRP
IL-1bb 0.60 (0.02–3.06)
ns versus P-PRP
p\ 0.017 versus L-PRP
0.45 (0.04–0.77)
p\ 0.017 versus L-PRP
60.7 (31.74–146.19)
FGF-2 4.53 (1.66–6.11)









PDGF AB/BBb 523.27 (239.19–1,210.48)
p\ 0.017 versus P-PRP and L-PRP
7,348.61 (1,008.00–10,113.68)
p\ 0.017 versus L-PRP
29,371.89 (17,555.47–81,690.26)
TGF-b1c 10,740.87 (2,408.46–11,896.05)






p\ 0.017 versus L-PRP
95.76 (67.76–161.95)
p\ 0.017 versus L-PRP
226.79 (181.49–771.13)
Concentrations (pg/ml) evaluated after 7 days of incubation are reported. Results are expressed as medians and (interquartile ranges) of seven
donors
PPP platelet-poor plasma, P-PRP pure platelet-rich plasma, L-PRP leucocyte platelet-rich plasm, ns not significant p value
Comparisons among plasma preparations as determined by Friedman’s Anova test: ap\ 0.01; bp\ 0.005; cp\ 0.002
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vs. P-PRP; p\ 0.0005 vs. PPP). An inverse dose–
response influence was shown for all preparations (5 vs.
20 % p = 0.003), which was particularly evident for
L-PRP as confirmed by the Kendall Tau correlation
(p = 0.014) (Fig. 2). Conversely, L-PRP significantly
enhanced FGF-2 expression levels (p = 0.012 vs. P-PRP;
p = 0.006 vs. PPP), with no dose contribution (Fig. 2).
No differences were observed between P-PRP and PPP.
MMP-13 is one of the most important matrix-degrading
enzymes and its expression appeared to be inversely related
to concentration in all preparations, (5 vs. 10 % p = 0.002;
5 vs. 20 % p = 0.001) (Fig. 3). Concerning the tissue
Fig. 1 Gene expression
analysis of interleukin (IL)-
1beta, IL-8/CXCL8, IL-6, IL-
10, tumour necrosis factor
(TNF) alpha. Synovial
fibroblasts were treated for
7 days with 5, 10, 20 % of
L-PRP, P-PRP or PPP obtained
from each subject (n = 7). Gene
expression relative
quantification was performed,
and data are expressed as
number of molecules *100,000
GAPDH. Boxes indicate the 25
and 75 % percentiles, whiskers
indicate the minimum to
maximum values, and bars
indicate the median; p value
significances are shown in
tables beside each figure, as
determined by General Linear
Model statistical analysis and
Kendall Tau correlation; ns not
significant
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inhibitor of degrading matrix enzymes, TIMP-1, TIMP-3
and TIMP-4, only TIMP-4 was differently modulated by
the PRP preparations, in particular L-PRP determined a
statistically significant decrease in TIMP-4 expression
compared to P-PRP (p = 0.021), with no dose or combined
dose treatment effect (Fig. 3).
HA production and HA synthases (HAS) gene
expression
No effect of the different preparations was observed on HA
production or on gene expression of its synthases (Fig. 4).
Despite this lack of a preparation-dependent effect, dose
Fig. 2 Gene expression
analysis of hepatocyte growth
factor (HGF), fibroblast growth
factor (FGF)-2, transforming
growth factor (TGF) beta,
vascular endothelial growth
factor (VEGF). Synovial
fibroblasts were treated for
7 days with 5, 10, 20 % of
L-PRP, P-PRP or PPP obtained
from each subject (n = 7). Gene
expression relative
quantification was performed,
and data are expressed as
number of molecules *100,000
GAPDH. Boxes indicate the 25
and 75 % percentiles, whiskers
indicate the minimum to
maximum values, and bars
indicate the median; p value
significances are shown in
tables beside each figure, as
determined by General Linear
Model statistical analysis and
Kendall Tau correlation; ns not
significant
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treatment trend of HAS-2 gene expression level stimulated
by L-PRP was statistically different from that obtained by
stimulating cells with P-PRP (p = 0.011) (Fig. 4); indeed,
HAS-2 gene expression had an increasing course in the
presence of L-PRP (significant correlation with doses was
observed: Kendall Tau p = 0.014), whereas in the presence
of P-PRP, it remained stable.
HAS-3 gene expression modulation seemed to have an
inverse dose–response trend, not dependent on preparation
type (5 vs. 20 % p = 0.0002) (Fig. 4).
Fig. 3 Gene expression
analysis of cartilage matrix-
degrading enzyme
metalloproteinase-13 (MMP-13)
and tissue inhibitor of
metalloproteinase inhibitors
(TIMP-1,-3,-4). Synovial
fibroblasts were treated for
7 days with 5, 10, 20 % of
L-PRP, P-PRP or PPP obtained
from each subject (n = 7). Gene
expression relative
quantification was performed,
and data are expressed as
number of molecules *100,000
GAPDH. Boxes indicate the 25
and 75 % percentiles, whiskers
indicate the minimum to
maximum values, and bars
indicate the median; p value
significances are shown in
tables beside each figure, as
determined by General Linear
Model statistical analysis; ns not
significant
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Correlations between gene expression level and white
blood cells or platelet count
Both IL-1b and IL-8 expression levels were directly cor-
related with L-PRP white blood cell (WBC) count (IL-1
p = 0.0048, r = 0.59; IL-8/CXCL8 p = 0.0039,
r = 0.60). HGF mRNA expression showed an inverse
correlation with both WBC and platelet count (WBC
p = 0.0293, r = -0.50; platelets p\ 0.0001, r = -0.61).
Interestingly, MMP-13 expression inversely correlated
with L-PRP WBC content (p = 0.0331, r = -0.47).
TIMP-4 inversely correlated with PRP platelet count
(p = 0.0134, r = -0.31). HAS-2 and HAS-3 had,
respectively, direct and inverse correlation trends with
Fig. 4 Hyaluronic acid
modulation by PRP. Synovial
fibroblasts were treated for
7 days with 5, 10, 20 % of
L-PRP, P-PRP or PPP obtained
from each subject (n = 7).
Hyaluronic acid synthases 1-2-3
gene expression relative
quantification was performed,
and data are expressed as
number of molecules *100,000
GAPDH. Hyaluronic acid
protein production was
normalized per number of cells.
Boxes indicate the 25 and 75 %
percentiles, whiskers indicate
the minimum to maximum
values, and bars indicate the
median; p value significances
are shown in tables beside each
figure, as determined by General
Linear Model statistical analysis
and Kendall Tau correlation; ns
not significant
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L-PRP WBC count (HAS-2 p = 0.0052, r = 0.59; HAS-3
p = 0.0327, r = -0.49) (not shown).
Discussion
The main finding of the present study underlines that OA
synovial fibroblasts appeared to be differentially modulated
by L-PRP compared to P-PRP and PPP. Specifically,
L-PRP was able to sustain a long-term up-regulation of IL-
1b, IL-8/CXCL8 and FGF-2 gene expression levels com-
pared to PRP and PPP. Conversely, a lower expression of
TIMP-4 and HGF genes was found in the presence of
L-PRP compared to either P-PRP or PPP.
Both IL-1b and IL-8/CXCL8 are well-recognized as
pro-inflammatory agents, and their involvement in OA
pathogenesis is extensively reported [for review see 7, 26,
28, 56]. The up-regulation of these genes induced by
L-PRP might be ascribed to the most elevated levels
reached by PDGF and TGF-b in L-PRP secretome, as
previous studies reported that PDGF and TGF-b are able to
synergistically potentiate IL-1b and IL-8/CXCL8 expres-
sion in OA synoviocytes [11, 12, 50]. Furthermore, since
IL-1b is able to up-regulate both IL-8 and its own pro-
duction, another possible explanation might be the pre-
sence of higher levels of IL-1b detected in L-PRP
compared to those of P-PRP and PPP preparations, prob-
ably due to the WBC count. Indeed, IL-1b and IL-8
expression levels significantly correlate with WBC count
and for both factors there is a dose–response effect.
Among the growth factors analysed in this study, FGF-b
and HGF expressions were, respectively, up- and down-
modulated by the L-PRP preparation, with a dose–response
effect seen on HGF expression. Interestingly, FGF-2 and
HGF seemed to exert opposite effects on OA cartilage:
FGF-2 is considered to be a catabolic and anti-anabolic
inducer in human cartilage [35, 59], whereas HGF has been
shown to foster anti-inflammatory effects on human
chondrocyte, by down-modulating Nuclear Factor kappa B
[6], the main transcription factor regulating the inflamma-
tory process. However, FGF-2 and HGF exert a wide
spectrum of pleiotropic effects on OA cartilage and syno-
vium, including pro-angiogenetic properties [36, 40]. The
role of PRP in angiogenesis modulation is one of the main
focuses of several studies. Angiogenesis may favour tissue
repair, but it may also promote inflammation and the
contribution of angiogenesis to joint modification has been
extensively reported in OA [5, 38].
The present findings concerning HGF modulation in OA
synoviocytes are in line with the results obtained by Anitua
et al. [4], who described an inhibition of HGF production
by fibroblasts exposed to a secretome from a high number
of platelets. Conversely, since IL-1beta inhibited the OA
synovial production of HGF [2], the lowest levels of
expression reached by HFG in presence of L-PRP may also
be due to the potential inhibitory effect of the IL-1beta
present in the L-PRP preparation. Given the ability of
WBC to produce IL-1 beta, this hypothesis is supported by
evidence of the inverse correlation between HGF expres-
sion and WBC count.
Another key point of the present analysis is the effect
of the different PRP preparations on specific enzymes
that play a pivotal role in joint tissue remodelling:
MMP-13, one of the most important matrix-degrading
enzymes strongly involved in cartilage matrix breakdown
and OA pathogenesis, and TIMP-1, TIMP-3, TIMP-4,
tissue inhibitors of several matrix metalloproteinases able
to counteract their degrading actions. Interestingly,
MMP-13 was not differentially modulated by PRP
preparations and PPP, in agreement with previously
reported data concerning other MMPs, such as MMP-1
and MMP-3 [2].
Furthermore, a previous study [42] focused on tendon
explant response treated with different PRP products, pre-
pared according to an increasing concentration of leuco-
cytes and different platelet/leucocyte ratios, the expression
of MMP-13 was lower than that of the control group, in the
presence of all PRP preparations although no differential
expression of MMP-13 was found among the different
preparations. The present results seem to be in line with
these findings, since no differences were found between
MMP-13 gene expression level between L-PRP and P-PRP
stimulation. Unlike these authors, in the present study, no
differences were found in MMP-13 expression between
PPP and PRPs. This discrepancy might due to different
reasons: first, the different cells tested in the present study
(synovial tissue vs. tendon), given that tissue-specific
response elicited by PRP has been highlighted in several
studies [4, 41]; second, the different type of culture (iso-
lated cells vs. explants) and third, the period of observation
(7 days vs. 72 h).
These data together with the evidence that, in the present
study, MMP-13 expression appeared to be inversely related
to the increasing concentrations of the all different prepa-
rations (L-PRP, P-PRP, PPP) might support the hypothesis
that MMP-13 gene regulation is mainly influenced by
plasma proteome and/or by the ratio between platelet
secretome and plasma proteins, as suggested by other
authors [4], and not directly related to a single condition.
Concerning the TIMPs analysed, Anitua et al. [2] pre-
viously reported that platelet releasate appeared not to alter
TIMP-1 production by OA synovial cells. Consistently
with this finding, in the present study, TIMP-1 and TIMP-3
expression was not significantly modified by the different
preparations, whereas a lower expression level of TIMP-4
was found in the presence of L-PRP compared with P-PRP.
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Finally, because of the relevance of Hyaluronan in joint
homoeostasis, as an important component of cartilage
extracellular matrix and synovial fluid, another aim of the
present study was to investigate the influence of PRP
preparations on HA production by OA synoviocytes and on
the expression of the different HAS isoforms. HA is syn-
thesized at the plasma membrane by HAS, which are
present as 3 transmembrane forms (HAS1-2-3) [30].
In the present study, no treatment regulation of HAS
expression or HA production by the different PRP prepa-
rations or PPP was found, which is not in line with pre-
viously reported data [2]. This might be explained by the
culture period. In fact these authors described a regulation
of HA production after 72-h stimulation with PRP prepa-
rations, whereas the present authors maintained synovio-
cytes in culture for 7 days to reproduce the treatment
schedule used in clinical practice, the effect of PRP on HA
gene expression or production might no longer be visible
after 7 days. Conversely, a different effect of dose treat-
ment on HAS2 (L-PRP had an increased trend whereas
P-PRP remained stable) and an inverse dose–response
effect on HAS3 was noticed by the present authors (20 %
dose reduced HAS3, not dependent on the type of PRP
used). Although these enzymes catalyse the same reaction,
they differ in the size of their products [30]. HAS-3 pro-
duces linear polymers of HA of smaller molecular sizes
than those produced by HAS-1 and HAS-2. Furthermore,
HAS-2 produces the largest molecules of the three iso-
forms. Therefore, L-PRP might play a role in reducing
smaller molecular-sized polymers while enhancing larger
molecular size hyaluronan. This effect might be beneficial
because it is known that both the concentration and size of
HA are reduced in OA synovial fluid [23] and that these
small-sized HA molecules might have a proinflammatory
effect in animal models [16].
Surprisingly, no differential effect was found on OA
synoviocytes induced by P-PRP compared to PPP. These
results might be ascribed to the lower concentrations of
platelet secretome from P-PRP which might be insufficient
to sustain a relevant modulation of gene expression up to
7 days.
Taking into account the pattern of molecules modulated
by L-PRP and their role in joint homoeostasis, the overall
results that emerge from this study highlight that the net
effect of L-PRP might prompt an inflammatory activation
of OA synoviocytes, given the ability of this preparation to
induce, for at least 7 days, an enhancement of proinflam-
matory and procatabolic factors such as IL-1beta, IL-8, and
FGF-2 together with a lowering of TIMP-4 expression.
These results added to the evidence of a significant
correlation between leucocyte number and both IL-1
expression and IL-8 expression, together with the finding
of a significantly different dose–response trend observed
for IL-1 expression in the presence of L-PRP might support
the hotly debated hypothesis that leucocytes in PRP might
foster unwanted effects.
The potentiality of L-PRP preparation to induce pro-
inflammatory events has been reported by other authors,
both in human and animal model ‘‘in vitro’’ studies [10,
42].
Interestingly, a clinical study, recently published [21],
has underlined that the presence of leucocytes in the
‘‘double-spinning’’ preparation does not seem to influence
the therapeutic efficacy of PRP in the treatment of cartilage
degeneration and OA, even if the occurrence of minor
adverse events (swelling and pain) were more frequently
reported in this group of patients.
The results obtained in the aforementioned clinical study
might be partially related to the findings of the present
study, but this assertion remains a mere speculation, given
the limitations of ‘‘in vitro’’ tissue-specific studies that
cannot mirror the complexity of joint environment.
Another potential limitation of this study arise by the
consideration that, even if the majority of research studies
address the pathophysiology of synovial tissue focusing on
fibroblast-like synoviocytes, additional relevant cell types,
including monocytes, macrophages, T and B cells, are
present in synovium and actively and collectively operate
modulating the joint response [8, 53].
Further researches are needed to clarify the influence of
the different PRP components (platelets and leucocytes)
and their concentration on the bioactivity of PRP. Since
leucocyte–platelet interaction may promote the biosynthe-
sis of other factors that facilitate the resolution of inflam-
mation, such as lipoxins [31], and given their involvement
in immune-response [45], the optimization of their con-
centrations in PRP products might lead to minimizing or
avoiding the detrimental effects ascribed to leucocytes and
exploiting their beneficial properties.
As for clinical relevance, the evaluation of the optimal
cell concentrations and their ratio (relative proportions) in
PRP will be important issues for future directions.
Further studies need to focus on the contribution of PRP
components to the overall observed clinical outcome,
helping to develop concentrates with specific and desired
effects.
Conclusion
The present data on OA synoviocytes indicate, on one
hand, that, at 7 days, P-PRP was not able to exert a dif-
ferential pattern of biological effect compared to PPP, and,
on the other hand, that L-PRP is able to sustain long-term
up-regulation of proinflammatory factors, such as IL-1beta,
IL-8 and FGF-2, together with a down-modulation of HGF
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and TIMP-4 expression, two factors that have been rec-
ognized as anti-catabolic mediators in cartilage, thus sup-
porting the need to further optimize PRP preparations to be
applied in the clinical practice.
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